EPIDAREX CAPITAL – CATALYZING INNOVATION IN HEALTH SCIENCE AND TECHNOLOGY
NEWS
Topas Therapeutics Extends its Series A to EUR 18 Million (USD 21 Million) with Boehringer Ingelheim Venture Fund
Corporate venture fund invests EUR 4 million (USD 5 million) into Topas Financing to accelerate clinical trials in autoimmune diseases Detlev Mennerich, Ph.D., Investment Manager
Epidarex Capital Appoints Three Leading Industry Executives to its Advisory Board
Bethesda, Maryland, USA, and Edinburgh, UK: Epidarex Capital (“Epidarex”), an early-stage, transatlantic life science venture fund, announces the appointment of Dr. William R Sellers, William
Topas Therapeutics Appoints Rupert Sandbrink, M.D., Ph.D., as Chief Development Officer and Chief Medical Officer
Highly accomplished pharmaceutical executive with many years of clinical development, medical affairs, and regulatory experience at Bayer and Schering To lead Topas’ clinical development and
Edinburgh Molecular Imaging Commences Phase II European Cancer Trial
Novel Compound with Potential for Early Detection and to Guide Treatment of Colorectal Cancer Edinburgh, UK, September 20, 2017 – Edinburgh Molecular Imaging (EM Imaging),
Apellis Pharmaceuticals Announces That APL-2 Met Its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
Statistically Significant Slowing of Disease Progression Seen at 12 Months Louisville, Kentucky, August 24, 2017 – Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a
Topas Therapeutics Signs Multi-Year Research and Option Agreement with Lilly Focused on Immune Tolerance
Work will utilize Topas’ novel approach for antigen-specific tolerance induction Lilly has option to in-license and further develop drug candidates produced under the collaboration
Apellis Pharmaceuticals Announces $60 Million Series E Financing
Funding Will Advance Trials of APL-2 in Paroxysmal Nocturnal Hemoglobinuria. Louisville, Kentucky, August 10, 2017 – Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a platform
Epidarex Capital Portfolio Company, Confluence Life Sciences, Acquired by Aclaris Therapeutics
August 10, 2017 – Epidarex Capital (“Epidarex”), an early stage life science venture capital firm, is pleased to announce the latest exit from its portfolio with